Autobio(SH:603658) Sou Hu Cai Jing·2025-07-24 11:27Group 1 - Company AnTuo Bio closed at 39.87 yuan, up 3.32%, with a rolling PE ratio of 19.98, marking a new low in 63 days, and a total market value of 22.783 billion yuan [1] - The average PE ratio for the medical device industry is 54.56, with a median of 37.54, placing AnTuo Bio at 42nd in the industry ranking [1] - As of the first quarter of 2025, three institutions hold shares in AnTuo Bio, with a total of 12.716 million shares valued at 477 million yuan [1] Group 2 - AnTuo Bio specializes in the research, manufacturing, integration, and service of in vitro diagnostic reagents and instruments, with key products including immunodiagnostic reagents, microbiological testing reagents, molecular diagnostic reagents, biochemical reagents, and instruments [1] - The company was listed among the "Top 100 Pharmaceutical Companies in China for 2023" and achieved second place in the "Top 100 Pharmaceutical Companies R&D Index" due to its outstanding performance in R&D results and support indices [1] - In the latest performance report for the first quarter of 2025, AnTuo Bio reported revenue of 996 million yuan, a year-on-year decrease of 8.56%, and a net profit of 270 million yuan, down 16.76%, with a gross profit margin of 65.07% [1]